Letters to the Editor
Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis. Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
R. Castellanos-Moreira1, A. Gomez2, I. Haro3, V. Ruiz-Esquide4, S. Marsal5, R. Sanmarti6
- Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Spain.
- Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona, Spain.
- Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Consejo Superior de Investigaciones Científicas, Barcelona, Spain.
- Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Spain.
- Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona, Spain
- Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Spain. sanmarti@clinic.cat
CER14163
2021 Vol.39, N°5
PI 1142, PF 1143
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 33666163 [PubMed]
Received: 28/10/2020
Accepted : 27/11/2020
In Press: 03/03/2021
Published: 31/08/2021
